1	4	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Discussion	_	_	NN	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	present	_	_	JJ	_	_	_	_	_
4	study	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	we	_	_	PRP	_	_	_	_	_
7	performed	_	_	VBD	_	_	_	_	_
8	16s	_	_	NNS	_	_	_	_	_
9	rRNA	_	_	NN	_	_	_	_	_
10	deep	_	_	JJ	_	_	_	_	_
11	sequencing	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	obtained	_	_	VBD	_	_	_	_	_
14	large	_	_	JJ	_	_	_	_	_
15	amounts	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	data	_	_	NNS	_	_	_	_	_
18	concerning	_	_	VBG	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	microbial	_	_	JJ	_	_	_	_	_
21	composition	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	diversity	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	abundance	_	_	NN	_	_	_	_	_
27	in	_	_	IN	_	_	_	_	_
28	healthy	_	_	JJ	_	_	_	_	_
29	subjects	_	_	NNS	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	RA	_	_	NN	_	_	_	_	_
32	patients	_	_	NNS	_	_	_	_	_
33	with	_	_	IN	_	_	_	_	_
34	various	_	_	JJ	_	_	_	_	_
35	clinical	_	_	JJ	_	_	_	_	_
36	phenotypes	_	_	NNS	_	_	_	_	_
37	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	results	_	_	NNS	_	_	_	_	_
3	have	_	_	VBP	_	_	_	_	_
4	demonstrated	_	_	VBN	_	_	_	_	_
5	that	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	lower	_	_	JJR	_	_	_	_	_
8	abundance	_	_	NN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	evenness	_	_	NN	_	_	_	_	_
11	of	_	_	IN	_	_	_	_	_
12	gut	_	_	NN	_	_	_	_	_
13	microbiota	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	RA	_	_	NN	_	_	_	_	_
16	patients	_	_	NNS	_	_	_	_	_
17	compared	_	_	VBN	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	healthy	_	_	JJ	_	_	_	_	_
20	subjects	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	with	_	_	IN	_	_	_	_	_
23	α-diversity	_	_	NN	_	_	_	_	_
24	lower	_	_	JJR	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	RF-positive	_	_	JJ	_	_	_	_	_
27	or	_	_	CC	_	_	_	_	_
28	ACPA-positive	_	_	JJ	_	_	_	_	_
29	RA	_	_	NNP	_	_	_	_	_
30	patients	_	_	NNS	_	_	_	_	_
31	than	_	_	IN	_	_	_	_	_
32	healthy	_	_	JJ	_	_	_	_	_
33	subjects	_	_	NNS	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	Using	_	_	VBG	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	permutational	_	_	JJ	_	_	_	_	_
4	multivariate	_	_	NN	_	_	_	_	_
5	analysis	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	variance	_	_	NN	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	PERMANOVA	_	_	NN	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	β-diversity	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	gut	_	_	NN	_	_	_	_	_
16	microbiota	_	_	NN	_	_	_	_	_
17	in	_	_	IN	_	_	_	_	_
18	healthy	_	_	JJ	_	_	_	_	_
19	subjects	_	_	NNS	_	_	_	_	_
20	was	_	_	VBD	_	_	_	_	_
21	significantly	_	_	RB	_	_	_	_	_
22	different	_	_	JJ	_	_	_	_	_
23	from	_	_	IN	_	_	_	_	_
24	that	_	_	DT	_	_	_	_	_
25	in	_	_	IN	_	_	_	_	_
26	RA	_	_	NN	_	_	_	_	_
27	patients	_	_	NNS	_	_	_	_	_
28	with	_	_	IN	_	_	_	_	_
29	different	_	_	JJ	_	_	_	_	_
30	phenotypes	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	phylum	_	_	NN	_	_	_	_	_
3	Verrucomicrobiae	_	_	NNP	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	genus	_	_	NN	_	_	_	_	_
6	Akkermansia	_	_	NNP	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	more	_	_	RBR	_	_	_	_	_
9	abundant	_	_	JJ	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	RA	_	_	NNP	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	compared	_	_	VBN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	healthy	_	_	JJ	_	_	_	_	_
16	subjects	_	_	NNS	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Among	_	_	IN	_	_	_	_	_
2	RA	_	_	NNP	_	_	_	_	_
3	patients	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	those	_	_	DT	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	higher	_	_	JJR	_	_	_	_	_
8	levels	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	TNF-α	_	_	NNP	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	IL-17A	_	_	NNP	_	_	_	_	_
13	had	_	_	VBD	_	_	_	_	_
14	increased	_	_	VBN	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	relative	_	_	JJ	_	_	_	_	_
17	abundance	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	phylum	_	_	NN	_	_	_	_	_
21	Gammaproteobacteria	_	_	NN	_	_	_	_	_
22	compared	_	_	VBN	_	_	_	_	_
23	to	_	_	TO	_	_	_	_	_
24	those	_	_	DT	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	lower	_	_	JJR	_	_	_	_	_
27	cytokine	_	_	NN	_	_	_	_	_
28	levels	_	_	NNS	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	RA	_	_	NNP	_	_	_	_	_
5	patients	_	_	NNS	_	_	_	_	_
6	exhibited	_	_	VBD	_	_	_	_	_
7	a	_	_	DT	_	_	_	_	_
8	different	_	_	JJ	_	_	_	_	_
9	microbial	_	_	JJ	_	_	_	_	_
10	composition	_	_	NN	_	_	_	_	_
11	which	_	_	WDT	_	_	_	_	_
12	was	_	_	VBD	_	_	_	_	_
13	related	_	_	VBN	_	_	_	_	_
14	to	_	_	TO	_	_	_	_	_
15	RF/ACPA	_	_	NNP	_	_	_	_	_
16	seropositivity	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	RA	_	_	NN	_	_	_	_	_
3	patients	_	_	NNS	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	either	_	_	CC	_	_	_	_	_
6	active	_	_	JJ	_	_	_	_	_
7	or	_	_	CC	_	_	_	_	_
8	inactive	_	_	JJ	_	_	_	_	_
9	status	_	_	NN	_	_	_	_	_
10	had	_	_	VBD	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	lower	_	_	JJR	_	_	_	_	_
13	α-diversity	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	gut	_	_	NN	_	_	_	_	_
16	microbial	_	_	JJ	_	_	_	_	_
17	taxa	_	_	NNS	_	_	_	_	_
18	than	_	_	IN	_	_	_	_	_
19	healthy	_	_	JJ	_	_	_	_	_
20	subjects	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	consistent	_	_	JJ	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	the	_	_	DT	_	_	_	_	_
25	findings	_	_	NNS	_	_	_	_	_
26	in	_	_	IN	_	_	_	_	_
27	Korean	_	_	JJ	_	_	_	_	_
28	patients	_	_	NNS	_	_	_	_	_
29	with	_	_	IN	_	_	_	_	_
30	early	_	_	JJ	_	_	_	_	_
31	RA	_	_	NNP	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Moreover	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	α-diversity	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	gut	_	_	NN	_	_	_	_	_
6	microbiota	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	lower	_	_	JJR	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	ACPA-positive	_	_	JJ	_	_	_	_	_
11	patients	_	_	NNS	_	_	_	_	_
12	compared	_	_	VBN	_	_	_	_	_
13	to	_	_	TO	_	_	_	_	_
14	HC	_	_	NNP	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	Chen	_	_	NNP	_	_	_	_	_
3	et	_	_	FW	_	_	_	_	_
4	al.	_	_	FW	_	_	_	_	_


1	revealed	_	_	VBD	_	_	_	_	_
2	similar	_	_	JJ	_	_	_	_	_
3	findings	_	_	NNS	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	significant	_	_	JJ	_	_	_	_	_
7	association	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	α-diversity	_	_	NN	_	_	_	_	_
10	with	_	_	IN	_	_	_	_	_
11	ACPA	_	_	NN	_	_	_	_	_
12	positivity	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	their	_	_	PRP$	_	_	_	_	_
15	RA	_	_	NN	_	_	_	_	_
16	patients	_	_	NNS	_	_	_	_	_
17	could	_	_	MD	_	_	_	_	_
18	not	_	_	RB	_	_	_	_	_
19	be	_	_	VB	_	_	_	_	_
20	reproduced	_	_	VBN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	the	_	_	DT	_	_	_	_	_
23	present	_	_	JJ	_	_	_	_	_
24	study	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	statistical	_	_	JJ	_	_	_	_	_
3	data	_	_	NNS	_	_	_	_	_
4	has	_	_	VBZ	_	_	_	_	_
5	suggested	_	_	VBN	_	_	_	_	_
6	that	_	_	IN	_	_	_	_	_
7	there	_	_	EX	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	no	_	_	DT	_	_	_	_	_
10	significant	_	_	JJ	_	_	_	_	_
11	difference	_	_	NN	_	_	_	_	_
12	which	_	_	WDT	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	be	_	_	VB	_	_	_	_	_
15	due	_	_	JJ	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	small	_	_	JJ	_	_	_	_	_
19	sample	_	_	NN	_	_	_	_	_
20	size	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	RA	_	_	NN	_	_	_	_	_
23	subgroups	_	_	NNS	_	_	_	_	_
24	with	_	_	IN	_	_	_	_	_
25	different	_	_	JJ	_	_	_	_	_
26	phenotypes	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	production	_	_	NN	_	_	_	_	_
6	of	_	_	IN	_	_	_	_	_
7	ACPA	_	_	NN	_	_	_	_	_
8	may	_	_	MD	_	_	_	_	_
9	be	_	_	VB	_	_	_	_	_
10	multifactorial	_	_	JJ	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	such	_	_	JJ	_	_	_	_	_
13	as	_	_	IN	_	_	_	_	_
14	genetic	_	_	JJ	_	_	_	_	_
15	factor	_	_	NN	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	smoking	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	severity	_	_	NN	_	_	_	_	_
22	of	_	_	IN	_	_	_	_	_
23	periodontitis	_	_	NN	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	After	_	_	IN	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	pooling	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	RF-positive	_	_	JJ	_	_	_	_	_
6	and	_	_	CC	_	_	_	_	_
7	ACPA-positive	_	_	JJ	_	_	_	_	_
8	patients	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	single	_	_	JJ	_	_	_	_	_
12	goup	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	significantly	_	_	RB	_	_	_	_	_
16	lower	_	_	JJR	_	_	_	_	_
17	α-diversity	_	_	NN	_	_	_	_	_
18	was	_	_	VBD	_	_	_	_	_
19	observed	_	_	VBN	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	seropositive	_	_	JJ	_	_	_	_	_
22	patients	_	_	NNS	_	_	_	_	_
23	compared	_	_	VBN	_	_	_	_	_
24	to	_	_	TO	_	_	_	_	_
25	seronegative	_	_	JJ	_	_	_	_	_
26	patients	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Regarding	_	_	VBG	_	_	_	_	_
2	the	_	_	DT	_	_	_	_	_
3	difference	_	_	NN	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	the	_	_	DT	_	_	_	_	_
6	β-diversity	_	_	NN	_	_	_	_	_
7	between	_	_	IN	_	_	_	_	_
8	healthy	_	_	JJ	_	_	_	_	_
9	subjects	_	_	NNS	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	RA	_	_	NN	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	PERMANOVA	_	_	NN	_	_	_	_	_
16	analysis	_	_	NN	_	_	_	_	_
17	showed	_	_	VBD	_	_	_	_	_
18	a	_	_	DT	_	_	_	_	_
19	significant	_	_	JJ	_	_	_	_	_
20	difference	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	phenotypes	_	_	NNS	_	_	_	_	_
23	characterized	_	_	VBN	_	_	_	_	_
24	by	_	_	IN	_	_	_	_	_
25	different	_	_	JJ	_	_	_	_	_
26	disease	_	_	NN	_	_	_	_	_
27	activity	_	_	NN	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	RF/ACPA	_	_	NN	_	_	_	_	_
30	status	_	_	NN	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	Table	_	_	NN	_	_	_	_	_
33	2	_	_	CD	_	_	_	_	_
34	)	_	_	-RRB-	_	_	_	_	_
35	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	weighted	_	_	JJ	_	_	_	_	_
3	UniFrac	_	_	NNP	_	_	_	_	_
4	distance	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	qualitative	_	_	JJ	_	_	_	_	_
7	measurement	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	phylogenetic	_	_	JJ	_	_	_	_	_
10	abundance	_	_	NN	_	_	_	_	_
11	difference	_	_	NN	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	showed	_	_	VBD	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	statistical	_	_	JJ	_	_	_	_	_
16	significance	_	_	NN	_	_	_	_	_
17	between	_	_	IN	_	_	_	_	_
18	RA	_	_	NN	_	_	_	_	_
19	patients	_	_	NNS	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	healthy	_	_	JJ	_	_	_	_	_
22	subjects	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	was	_	_	VBD	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	trend	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	difference	_	_	NN	_	_	_	_	_
7	finding	_	_	VBG	_	_	_	_	_
8	in	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	β-diversity	_	_	NN	_	_	_	_	_
11	between	_	_	IN	_	_	_	_	_
12	patients	_	_	NNS	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	lowest	_	_	JJS	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	highest	_	_	JJS	_	_	_	_	_
19	levels	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	TNF-α	_	_	NNP	_	_	_	_	_
22	or	_	_	CC	_	_	_	_	_
23	IL-17A	_	_	NNP	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	indicating	_	_	VBG	_	_	_	_	_
26	an	_	_	DT	_	_	_	_	_
27	association	_	_	NN	_	_	_	_	_
28	of	_	_	IN	_	_	_	_	_
29	gut	_	_	NN	_	_	_	_	_
30	microbiota	_	_	NN	_	_	_	_	_
31	composition	_	_	NN	_	_	_	_	_
32	with	_	_	IN	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	inflammatory	_	_	JJ	_	_	_	_	_
35	parameters	_	_	NNS	_	_	_	_	_
36	in	_	_	IN	_	_	_	_	_
37	RA	_	_	NNP	_	_	_	_	_
38	patients	_	_	NNS	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	Using	_	_	VBG	_	_	_	_	_
2	pre-trained	_	_	JJ	_	_	_	_	_
3	Naive	_	_	NNP	_	_	_	_	_
4	Bayes	_	_	NNP	_	_	_	_	_
5	Greengenes	_	_	NNP	_	_	_	_	_
6	classifier	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	explore	_	_	VB	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	taxonomic	_	_	JJ	_	_	_	_	_
11	composition	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	gut	_	_	NN	_	_	_	_	_
14	microbiota	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	we	_	_	PRP	_	_	_	_	_
17	observed	_	_	VBD	_	_	_	_	_
18	an	_	_	DT	_	_	_	_	_
19	increased	_	_	VBN	_	_	_	_	_
20	abundance	_	_	NN	_	_	_	_	_
21	of	_	_	IN	_	_	_	_	_
22	phylum	_	_	NN	_	_	_	_	_
23	Verrucomicrobiae	_	_	NNP	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	which	_	_	WDT	_	_	_	_	_
26	might	_	_	MD	_	_	_	_	_
27	be	_	_	VB	_	_	_	_	_
28	driven	_	_	VBN	_	_	_	_	_
29	by	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	genus	_	_	NN	_	_	_	_	_
32	Akkermansia	_	_	NNP	_	_	_	_	_
33	(	_	_	-LRB-	_	_	_	_	_
34	Akkermansia	_	_	FW	_	_	_	_	_
35	muciniphila	_	_	FW	_	_	_	_	_
36	)	_	_	-RRB-	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	in	_	_	IN	_	_	_	_	_
39	RA	_	_	NNP	_	_	_	_	_
40	patients	_	_	NNS	_	_	_	_	_
41	compared	_	_	VBN	_	_	_	_	_
42	with	_	_	IN	_	_	_	_	_
43	healthy	_	_	JJ	_	_	_	_	_
44	subjects	_	_	NNS	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	findings	_	_	NNS	_	_	_	_	_
3	support	_	_	VBP	_	_	_	_	_
4	the	_	_	DT	_	_	_	_	_
5	results	_	_	NNS	_	_	_	_	_
6	revealing	_	_	VBG	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	implication	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	Akkermansia	_	_	NNP	_	_	_	_	_
12	muciniphila	_	_	NN	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	pathogenesis	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	murine	_	_	NN	_	_	_	_	_
18	model	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	arthritis	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Akkermansia	_	_	NNP	_	_	_	_	_
2	has	_	_	VBZ	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	been	_	_	VBN	_	_	_	_	_
5	associated	_	_	VBN	_	_	_	_	_
6	with	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	proinflammatory	_	_	JJ	_	_	_	_	_
9	pathways	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	including	_	_	VBG	_	_	_	_	_
12	upregulation	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	B-	_	_	NN	_	_	_	_	_
15	and	_	_	CC	_	_	_	_	_
16	T-cell	_	_	NN	_	_	_	_	_
17	receptor	_	_	NN	_	_	_	_	_
18	signaling	_	_	NN	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	proinflammatory	_	_	JJ	_	_	_	_	_
3	effects	_	_	NNS	_	_	_	_	_
4	may	_	_	MD	_	_	_	_	_
5	be	_	_	VB	_	_	_	_	_
6	related	_	_	VBN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	its	_	_	PRP$	_	_	_	_	_
9	ability	_	_	NN	_	_	_	_	_
10	to	_	_	TO	_	_	_	_	_
11	degrade	_	_	VB	_	_	_	_	_
12	mucus	_	_	NN	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	thus	_	_	RB	_	_	_	_	_
15	increase	_	_	VB	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	exposure	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	resident	_	_	JJ	_	_	_	_	_
20	immune	_	_	JJ	_	_	_	_	_
21	cells	_	_	NNS	_	_	_	_	_
22	to	_	_	TO	_	_	_	_	_
23	gut	_	_	VB	_	_	_	_	_
24	microbial	_	_	JJ	_	_	_	_	_
25	antigens	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	contrast	_	_	NN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	previous	_	_	JJ	_	_	_	_	_
5	studies	_	_	NNS	_	_	_	_	_
6	revealing	_	_	VBG	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	predominance	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	Prevotella	_	_	NNP	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	gut	_	_	NN	_	_	_	_	_
15	microbiota	_	_	NN	_	_	_	_	_
16	was	_	_	VBD	_	_	_	_	_
17	associated	_	_	VBN	_	_	_	_	_
18	with	_	_	IN	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	untreated	_	_	JJ	_	_	_	_	_
21	or	_	_	CC	_	_	_	_	_
22	new-onset	_	_	JJ	_	_	_	_	_
23	RA	_	_	NN	_	_	_	_	_
24	and	_	_	CC	_	_	_	_	_
25	phylum	_	_	NN	_	_	_	_	_
26	Bacteroidetes	_	_	NNS	_	_	_	_	_
27	was	_	_	VBD	_	_	_	_	_
28	enriched	_	_	VBN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	early	_	_	JJ	_	_	_	_	_
31	RA	_	_	NNP	_	_	_	_	_
32	patients	_	_	NNS	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	we	_	_	PRP	_	_	_	_	_
35	did	_	_	VBD	_	_	_	_	_
36	not	_	_	RB	_	_	_	_	_
37	observe	_	_	VB	_	_	_	_	_
38	significant	_	_	JJ	_	_	_	_	_
39	increase	_	_	NN	_	_	_	_	_
40	in	_	_	IN	_	_	_	_	_
41	the	_	_	DT	_	_	_	_	_
42	abundance	_	_	NN	_	_	_	_	_
43	of	_	_	IN	_	_	_	_	_
44	family	_	_	NN	_	_	_	_	_
45	Prevotellaceae	_	_	NNP	_	_	_	_	_
46	or	_	_	CC	_	_	_	_	_
47	phylum	_	_	NN	_	_	_	_	_
48	Bacteroidetes	_	_	NNS	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	differences	_	_	NNS	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	patients	_	_	NNS	_	_	_	_	_
5	’	_	_	POS	_	_	_	_	_
6	characteristics	_	_	NNS	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	treatment	_	_	NN	_	_	_	_	_
9	regimens	_	_	NNS	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	our	_	_	PRP$	_	_	_	_	_
12	enrolled	_	_	VBN	_	_	_	_	_
13	patients	_	_	NNS	_	_	_	_	_
14	may	_	_	MD	_	_	_	_	_
15	explain	_	_	VB	_	_	_	_	_
16	this	_	_	DT	_	_	_	_	_
17	discrepancy	_	_	NN	_	_	_	_	_
18	.	_	_	.	_	_	_	_	_


1	It	_	_	PRP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	interesting	_	_	JJ	_	_	_	_	_
4	that	_	_	IN	_	_	_	_	_
5	active	_	_	JJ	_	_	_	_	_
6	RA	_	_	NN	_	_	_	_	_
7	patients	_	_	NNS	_	_	_	_	_
8	have	_	_	VBP	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	increased	_	_	VBN	_	_	_	_	_
11	abundance	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	Collinsella	_	_	NNP	_	_	_	_	_
14	compared	_	_	VBN	_	_	_	_	_
15	with	_	_	IN	_	_	_	_	_
16	inactive	_	_	JJ	_	_	_	_	_
17	RA	_	_	NN	_	_	_	_	_
18	patients	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	arthrogenic	_	_	JJ	_	_	_	_	_
3	role	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	Collinsella	_	_	NNP	_	_	_	_	_
6	has	_	_	VBZ	_	_	_	_	_
7	been	_	_	VBN	_	_	_	_	_
8	confirmed	_	_	VBN	_	_	_	_	_
9	both	_	_	CC	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	vivo	_	_	NN	_	_	_	_	_
12	using	_	_	VBG	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	humanized	_	_	VBN	_	_	_	_	_
15	murine	_	_	NN	_	_	_	_	_
16	model	_	_	NN	_	_	_	_	_
17	of	_	_	IN	_	_	_	_	_
18	arthritis	_	_	NN	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	vitro	_	_	FW	_	_	_	_	_
22	by	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	human	_	_	JJ	_	_	_	_	_
25	intestinal	_	_	JJ	_	_	_	_	_
26	epithelium	_	_	NN	_	_	_	_	_
27	cell-based	_	_	JJ	_	_	_	_	_
28	study	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_
30	Chen	_	_	NNP	_	_	_	_	_
31	et	_	_	FW	_	_	_	_	_
32	al.	_	_	FW	_	_	_	_	_
33	further	_	_	RBR	_	_	_	_	_
34	demonstrated	_	_	VBD	_	_	_	_	_
35	that	_	_	IN	_	_	_	_	_
36	Collinsella	_	_	NNP	_	_	_	_	_
37	could	_	_	MD	_	_	_	_	_
38	be	_	_	VB	_	_	_	_	_
39	transferred	_	_	VBN	_	_	_	_	_
40	to	_	_	TO	_	_	_	_	_
41	germ-free	_	_	JJ	_	_	_	_	_
42	mice	_	_	NNS	_	_	_	_	_
43	with	_	_	IN	_	_	_	_	_
44	resultant	_	_	JJ	_	_	_	_	_
45	exacerbation	_	_	NN	_	_	_	_	_
46	of	_	_	IN	_	_	_	_	_
47	arthritis	_	_	NN	_	_	_	_	_
48	in	_	_	IN	_	_	_	_	_
49	a	_	_	DT	_	_	_	_	_
50	murine	_	_	NN	_	_	_	_	_
51	model	_	_	NN	_	_	_	_	_
52	.	_	_	.	_	_	_	_	_


1	These	_	_	DT	_	_	_	_	_
2	observations	_	_	NNS	_	_	_	_	_
3	suggest	_	_	VBP	_	_	_	_	_
4	a	_	_	DT	_	_	_	_	_
5	potential	_	_	JJ	_	_	_	_	_
6	role	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	Collinsella	_	_	NNP	_	_	_	_	_
10	expansion	_	_	NN	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	pathogenesis	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	active	_	_	JJ	_	_	_	_	_
16	RA	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_

